1	TITLE
2	HIV-1 5'-Leader Mutations in Plasma Viruses Before and After the Development of Reverse Transcriptase
3	Inhibitor-Resistance Mutations
4	
5	SHORT TITLE
6	HIV-1 5'-Leader Plasma Virus Sequences
7	
8 9	AUTHORS
10	Janin Nouhin ¹ *, Philip L. Tzou ² *, Soo-Yon Rhee ² *, Malaya K. Sahoo ³ , Benjamin A. Pinsky ⁴ , Miri Krupkin ⁵ ,
11	Joseph D. Puglisi ⁵ , Elisabetta V. Puglisi ⁵ , Robert W. Shafer ²
12	
13	*Each of these authors contributed equally to the work
14	
15	AFFILIATIONS
16	¹ Division of Infectious Diseases, Stanford University, Stanford, CA, USA and Virology Unit, Institut
17	Pasteur du Cambodge, Pasteur Network, Phnom Penh, Cambodia; ² Division of Infectious Diseases,
18	Stanford University, Stanford, CA, USA; 3 Department of Pathology, Stanford University, Stanford, CA,
19	USA; 4 Division of Infectious Diseases, Department of Medicine, Stanford University, Stanford, CA, USA;
20	Department of Pathology, Stanford University, Stanford, CA, USA; 5 Department of Structural Biology,
21	Stanford University School of Medicine, Stanford, CA, USA.
22	
23	Corresponding authors: PLT (<u>philiptz@stanford.edu</u>), RWS (<u>rshafer@stanford.edu</u>)
24	Abstract word count: 300
25	Text word count: 2,897

,		٩	í.	
	1			
2	ć			
			•	

26

ABSTRACT

27 Background: HIV-1 RT initiation depends on interaction between viral 5'-leader RNA, RT, and host 28 tRNA3_{Lvs}. We therefore sought to identify co-evolutionary changes between the 5'-leader and RT in 29 viruses developing RT-inhibitor resistance mutations. Methods: We sequenced 5'-leader positions 37-30 356 of paired plasma virus samples from 29 individuals developing the NRTI-resistance mutation M184V, 31 19 developing an NNRTI-resistance mutation, and 32 untreated controls. 5'-leader variants were defined 32 as positions where \geq 20% of NGS reads differed from the HXB2 sequence. Emergent mutations were 33 defined as nucleotides undergoing \geq 4-fold change in proportion between baseline and follow-up. 34 Mixtures were defined as positions containing ≥ 2 nucleotides each present in $\geq 20\%$ of NGS reads. 35 Results: Among 80 baseline sequences, 87 positions (27.2%) contained a variant; 52 contained a 36 mixture. Position 201 was the only position more likely to develop a mutation in the M184V (9/29 vs. 37 0/32; p=0.0006) or NNRTI-resistance (4/19 vs. 0/32; p=0.02; Fisher's Exact Test) groups than the control 38 group. Mixtures at positions 200 and 201 occurred in 45.0% and 28.8%, respectively, of baseline 39 samples. Because of the high proportion of mixtures at these positions, we analyzed 5'-leader mixture 40 frequencies in two additional datasets: five publications reporting 294 dideoxyterminator clonal 41 GenBank sequences from 42 individuals and six NCBI BioProjects reporting NGS datasets from 295 42 individuals. These analyses demonstrated position 200 and 201 mixtures at proportions similar to those 43 in our samples and at frequencies several times higher than at all other 5'-leader positions. Conclusions: 44 Although we did not convincingly document co-evolutionary changes between RT and 5'-leader 45 sequences, we identified a novel phenomenon, wherein positions 200 and 201, immediately 46 downstream of the HIV-1 primer binding site exhibited an extraordinarily high likelihood of containing a 47 nucleotide mixture. Possible explanations for the high mixture rates are that these positions are 48 particularly error-prone or provide a viral fitness advantage.

3

4	.9

INTRODUCTION

50 The first 356 nucleotides of the RNA genome, the 5'-leader extends from the start of the 51 transactivating response (TAR) element at HXB2 position 455 in the proviral DNA sequence to HXB2 52 position 810 [1]. The 5'-leader structure and functions have been studied using phylogenetic methods 53 [2], biochemical experiments with site-directed mutants [3–5], RNA structural probing methods [6,7], 54 NMR [8], and cryo-EM [9,10]. These and many other studies have shown that the 5'-leader has multiple 55 functional units including TAR, which is required for initiating transcription; several RNA elements 56 required for RT initiation including the nearly invariant primer binding site (PBS); and several 57 downstream elements responsible for viral splicing, dimerization, and packaging [1,4,8,9,11,12].

The 5'-leader region adapts at least two conformations including a monomeric form that interacts with the cellular translation machinery to favor the synthesis of HIV-1 proteins and a dimeric form that results in genomic packaging and virus assembly (reviewed in [13,14]). The 5'-leader also initiates reverse transcription through a three-way interaction among the viral RNA genome, the reverse transcriptase (RT) enzyme, and tRNA3_{Lys} (reviewed in [4,15]). During RT initiation, RT binds to the viral RNA-tRNA3_{Lys} duplex forming the reverse transcription initiation complex [9].

64 RT initiation represents a bottleneck to HIV-1 replication as evidenced by an approximately 100-65 3000-fold reduced rate of nucleotide incorporation during initiation compared with elongation and by 66 the much slower synthesis of the first 200 HIV-1 nucleotides compared to the remaining nucleotides of 67 proviral DNA [15]. We hypothesized that during RT initiation there may be an interplay between changes 68 in RT and the 5'-leader viral RNA. In particular, we questioned whether the 5'-leader would evolve to 69 adapt to the development of drug-resistance mutations (DRMs) in the RT enzyme. Therefore, we 70 sequenced the 5'-leader region of plasma virus samples obtained from individuals before and after the 71 development of the most common nucleoside RT inhibitor (NRTI) mutation M184V, which confers

4

resistance to the cytidine analogs lamivudine (3TC) and emtricitabine (FTC), or a non-nucleoside RT
 inhibitor (NNRTI)-resistance mutation.

- 74
- 75

<u>METHODS</u>

76 Individuals and samples

77 We identified individuals undergoing two or more genotypic resistance tests at different times 78 for clinical purposes who had cryopreserved remnant plasma samples meeting one of the following 79 criteria: (1) Had a baseline sample lacking the 3TC/FTC-resistance mutation M184V/I and a follow-up 80 sample containing M184V ("M184V group"); (2) Had a baseline sample lacking an NNRTI-resistance 81 mutation and a follow-up sample containing an NNRTI-resistance mutation ("NNRTI group"); and (3) Had 82 two or more samples at different times lacking M184V/I or an NNRTI resistance mutation ("Control 83 group"). Individuals meeting the first criteria were required to not have a history of a sample with 84 M184V/I and individuals meeting the second criteria were required to not have a history of a sample 85 with an NNRTI-resistance mutation. To be eligible for next-generation sequencing (NGS), samples were 86 required to have a plasma HIV-1 RNA level \geq 10,000 copies/ml.

The remnant plasma samples used in this study were obtained between the years 2000 and 2017. The Stanford University Institutional Review Board approved this study under protocol 6633, entitled "Human Immunodeficiency Virus Quasispecies During Antiviral Therapy". The approval included a waiver of consent because the study used anonymized de-identified data and remnant plasma samples. The samples were sequenced and the data were collected for research purposes between July 2019 and January 2021.

93

94 Sequencing protocol

5

95 Total nucleic acids were extracted from 200 uL of plasma using the EZ1 Virus Mini Kit V2.0 on 96 the automated EZ1 advanced XL (both from Qiagen), according to manufacturer's instructions. Nucleic 97 acids were eluted in 60uL of AVE buffer and the 5'-leader region was amplified using the following 98 amplification strategy. First, one-step RT-PCR (SuperScript III) was performed using HIV-1 specific 99 primers with 5' tags to enable sample indexing during a second PCR. The PCR primers were 100 complementary to HXB2 positions 469-490 (5'-GACCAGATCTGAGCCTGGGAGC) and 863-844 (5'-101 CCCCCTGGCCTTAACCGAAT). The resulting amplicon encompassed HXB2 positions 491-843 which 102 included the 5'-leader positions 37-356. A second PCR was then performed to multiplex samples with 103 dual indexes using NEBNext Multiplex Oligos for Illumina (New England Biolabs). Library quality and 104 concentration were measured using the Agilent DNA 1000 kit (Agilent Technologies). The PCR products 105 showing non-specific peaks were purified again using E-gel SizeSelect II Agarose Gel, 2% (Invitrogen) 106 according to manufacturer's instructions. Amplicons were pooled at equimolar concentration and 107 purified using AMPure XP beads (Beckman Coulter). The library was spiked with 12.5% PhiX and loaded 108 onto an Illumina MiSeq v2 Cartridge at 8 pM and was sequenced using 2 x 250 bp runs. Both ends of 109 each DNA fragment were sequenced (i.e., paired-end sequencing) to obtain bi-directional sequence 110 information.

111

112 Sequence analysis pipeline

113 The Fastp program was applied to each FASTQ file to trim adapters, remove regions with low 114 phred scores, and stich paired reads [16]. Trimmed sequence reads were aligned to the HXB2 5'-leader 115 sequence using Minimap2 and the alignments were saved in Sequence Alignment Map (SAM) text files 116 [17]. Samtools were used to convert the resulting SAM text files into binary BAM files and BAI index files 117 [18]. PySam was used to read each BAM file to construct nucleotide frequency files containing the 118 proportions of each nucleotide and indel at each 5'-leader position. Paired samples for which both

6

baseline and follow-up contained a read depth of ≥200 at all 5'-leader positions between 37 and 356
were retained for analysis.

We then created consensus sequences using IUPAC codes, whenever one or more nucleotide was present in ≥20% of sequence reads at the same position. These sequences were submitted to GenBank (accession numbers: OQ814268-OQ814427) and used to construct a neighbor-joining phylogenetic tree. The phylogenetic tree employed a weighted distance matrix, which utilized the Jaccard distance to account for the overlap among nucleotides when more than one nucleotide was present at the same position. The 160 unedited fastq files were submitted to the NCBI Sequence Read Archive (BioProject PRJNA954829).

For each baseline and follow-up sequence, we reported all nucleotides, insertions, and deletions present in $\geq 20\%$ of sequence reads. Mutational changes between baseline and follow-up were defined as nucleotides or indels for which the proportion of reads containing them changed by \geq 4-fold and that were present at follow-up in $\geq 20\%$ of reads. This requirement therefore occasionally necessitated noting which nucleotides and indels in the baseline sequence were present between 5% and 20% of reads.

133

134 Analysis of previously published HIV-1 group M 5'-leader sequences

<u>One-per-person sequence set:</u> We searched the June 2021 version of the Los Alamos National Laboratory HIV Sequence Database (LANL) for non-problematic HIV-1 5'-leader group M sequences with a minimal length of 250 nucleotides. Sequences were grouped into submission sets according to the GenBank "Title" and "Author" fields. Submission sets that were not linked to a PubMed reference or that contained sequences from fewer than five persons were excluded from analysis. When multiple sequences were available for the same person, we randomly selected one sequence for analysis. The search yielded 85 studies containing 1,417 one-per-person 5'-leader sequences.

7

Each sequence was first aligned to the HXB2 reference 5'-leader sequence using the Smith-Waterman algorithm included in the European Molecular Biology Open Software Suite (EMBOSS) package [19]. Next a multiple sequence alignment of the 5'-leader regions was performed using MAFFT with a set of 157 pre-aligned subtype reference sequences from LANL as a seed alignment using the option for adding unaligned sequences [20]. The alignment was then manually adjusted to increase the consistency of indel placement. For each 5'-leader position we determined the frequency of each nucleotide and each indel.

149 <u>Clonal sequences set:</u> Among the 85 publications reporting HIV-1 group M 5'-leader sequences 150 from \geq 5 persons, we identified five publications that reported an average of at least three clones per 151 person with active virus replications [21–25]. Four publications reporting at least three clones per 152 person were excluded because the clones were from proviral DNA samples from persons with virological 153 suppression and they contained large numbers of deletions.

<u>NGS set:</u> We reviewed the NCBI Sequence Read Archive (SRA) to identify published studies in which NGS encompassed the 5'-leader in at least five persons. We analyzed the sequences from each of these studies using the NGS pipeline described above ("Sequence analysis section"). Overall, there were 246 SRA BioProjects including 63 containing 5'-leader sequences as determined by our sequence analysis pipeline. Six publications contained sequences from 295 persons (between 8 and 105 persons per publication) [7,26–30].

- 160
- 161

<u>RESULTS</u>

162 Individuals and samples

Samples before and after ART were available for 29 individuals who developed M184V and for 164 19 individuals who developed an NNRTI-resistance mutations including K103N (n=13), Y181C (n=5), and 165 G190A (n=1). Samples from two time points were available from 32 control individuals who were ART-

8

166 naïve and who did not develop any RTI-resistance mutations. Table 1 summarizes the demographics, 167 ART histories, and baseline laboratory values for each group of individuals. Among the 29 individuals in 168 the M184V group, 19 were NRTI-naïve at the time of the first sample. Nine had previously received 3TC 169 or FTC but never developed M184V; one had received NRTIs other than 3TC or FTC. Among the 19 170 individuals in the NNRTI-resistance group, 16 were NNRTI-naïve and three had previously received an 171 NNRTI but never developed NNRTI resistance.

172 At the time the initial plasma samples were obtained, the individuals in the control group had a 173 higher median CD4 count (402.5 cells/mm³) compared to those in the M184V (83 cells/mm³) and NNRTI-174 resistance (160 cells/mm³) groups. At the time of follow-up sampling, the median CD4 count in the 175 control group decreased while the median CD4 count in the M184V and NNRTI groups increased (Table 176 1). The median time between the two samples differed between the three groups: 12.5 months for the 177 control group, 20 months for the M184V group, and 39 months for the NNRTI-resistance group. The 178 median uncorrected genetic distance in the protease and RT genes was 0.75% for the individuals in the 179 control group compared with 2.17% and 1.92% in the M184V and NNRTI-resistance groups, respectively.

180

181 **Baseline sequences**

The median number of reads per sample was 2883 (IQR: 1264 - 4981). Within each sample, the coverage was highly uniform across positions 37-356. Across all samples, 98.4% of paired reads encompassed \geq 300 nucleotides. All of the sequences belonged to subtype B based on phylogenetic analysis of the *pol* gene. Among the 80 baseline sequences, 87 (27.2%) positions had a nucleotide difference from HXB2 present in \geq 20% of sequence reads (Figure 1). At positions 47, 200, 201, 213, 227, 265, and 305 more than one-half of the nucleotides differed from HXB2 but were the same as the subtype B consensus sequence.

9

The poly A motif (AATAAA; positions 73-78), primer activating signal (PAS; positions 125-130) and primer binding site (PBS; positions 182-199) were completely conserved in the 80 baseline sequences. The U5 region was represented by CGT (91% of sequences) or CAT (9% of sequences) each of which maintained complementarity to the Matrix initiation codon (positions 336-338). The dimerization signal (DIS; positions 257-262) was represented by GCGCGC in all but five sequences. The RNA packaging signal (PSI; positions 312-325) contained the same nucleotides in all but three sequences.

Figure 2 shows that the distribution of nucleotides and indels was highly similar between the 80 baseline samples and the 1,417 samples downloaded from the LANL database (Supplementary Figure 1). There were no apparent differences in the proportions of nucleotides or indels between the sequences from the 56 individuals who were ART-naïve and the 24 individuals who were ART-experienced at baseline (Supplementary Figure 2). Figure 3 shows that 52 positions had more than one nucleotide detected in \geq 20% of sequence reads. At positions 200, 201, 304, 224, and 354, more than 10% of samples had a mixture of two nucleotides.

Among the 56 individuals who were ART-naïve at the time baseline sequencing was performed, 203 22 were found by Sanger sequencing of the *pol* gene to have ambiguous nucleotides (i.e., mixtures) at 204 <0.5% of positions, an established marker suggestive of recent infection [31,32] while 34 were found to 205 have ambiguous nucleotides at $\ge 0.5\%$ of positions. The probabilities of having mixtures at positions 200 206 and 201 were significantly correlated with the proportion of ambiguous nucleotides in pol (position 200: 207 spearman rho=0.28, p=0.03; position 201: spearman rho=0.33; p=0.01).

208 Compared to HXB2, two individuals had large deletions. In one individual, positions 119 to 161 209 were deleted and in the other individual, positions 281 to 288 were deleted. Both of these deletions 210 were also present in the follow-up sequence from the same individual suggesting that these deletions 211 were not sequencing artifacts. An additional 42 baseline samples had deletions of 1 to 3 nucleotides. 212 The most frequent positions with deletions were between positions 301 to 303 (20 samples) and

10

between positions 150 to 153 (13 samples). Compared to HXB2, 54 samples had one or more insertions,
with the most frequent occurring between positions 300 to 305 (26 samples), 254 to 255 (6 samples),
165 to 167 (5 samples), and 198 to 202 (4 samples). Eight samples had insertions containing more than
three nucleotides.

217

218 Follow-up sequences

Figure 4 summarizes the number of individuals by the number of positions at which a \geq 4-fold change in the proportion of a nucleotide or indel occurred between baseline and follow-up for each of the three sample groups. The median number of changes per individual was higher in the M184V (3; IQR:1-4; p=0.014 Wilcoxon Rank Sum Test) and NNRTI groups (2; IQR: 1-4; p=0.12; Wilcoxon Rank Sum Test) than in the control group (0.5; IQR:0-4). The three control group individuals with large changes included one individual who may have experienced a re-infection as evidenced by a nucleotide distance of 5.4% between their baseline and follow-up HIV-1 *pol* sequence.

Fifty-three of the 63 deletions found in either baseline or follow-up samples were present at both time points. Fifty-three of the 70 insertions present in either baseline or follow-up samples were present at both time points. A neighbor-joining phylogenetic tree using the Jaccard distance to weight the distance between overlapping IUPAC nucleotides is shown in Figure 5.

Figure 6A shows the positions at which at least one nucleotide changed its proportion by \geq 4-fold and which occurred in \geq 20% of sequence reads. The positions at which nucleotide changes occurred most frequently are shown in Figure 6B. Positions 200 and 201, which were the positions most likely to have mixtures at baseline, were also the positions most likely to exhibit a \geq 4-fold change in the proportion of a nucleotide. Position 201 was significantly more likely to exhibit a \geq 4-fold change in its proportions in the M184V (9/29 vs. 0/32; p=0.0006; Fisher's Exact Test) and the NNRTI-resistance groups

11

(4/19 vs. 0/32; p=0.02; Fisher's Exact Test) compared with the control group. There were no significant
 differences between each of the three groups at any other position including position 200.

Although position 201 frequently displayed a change between baseline and follow-up in the M184V and NNRTI groups, there was no consistent pattern of nucleotide change. For example, among the nine individuals in the M184V group that experienced a 4-fold change in the proportion of a nucleotide, the baseline nucleotides were C in five individuals, T in three individuals, and G in one individual. Among the five individuals with C at baseline, four changed to T and one to G. Among the three individuals with T at baseline, one changed to C, another to G, and the third to G and A. The one individual with G changed to T.

245

246 Distribution of mixtures in previously published clonal sequences and in NGS

The five publications describing a minimum of three clones per individual from at least five individuals reported a total of 294 sequences from 42 individuals. At five positions, $\geq 10\%$ of individuals had a mixture of ≥ 2 nucleotides in different clones including positions 200 (n=16 individuals; 38.1%), 201 (n=11 individuals; 26.2%), 305 (n=7 individuals; 16.7%), 152 (n=5 individuals; 11.9%), and 281 (n=5 individuals; 11.9%).

The six publications in the NCBI SRA containing 5'-leader sequences from 295 individuals reported that the most common positions containing a mixture with at least two nucleotides (i.e., each present in $\geq 20\%$ of NGS reads) were also positions 200 (n=103 individuals; 34.9%) and 201 (n=62 individuals; 21.1%). Table 2 illustrates the 15 positions that most frequently contained mixtures in this study and the frequency with which these positions contained mixtures in the GenBank and NCBI SRA datasets. In contrast to the 5'-leader, among 384 RT sequences from 379 individuals in the same six NCBI SRA dataset publications, no position had a mixture in $\geq 6\%$ of positions.

12

7	6	n
2	υ	υ

DISCUSSION

To our knowledge, this is one of the largest studies of 5'-leader sequences in persons living with HIV-1 and the first study of paired HIV-1 5'-leader sequences from individuals who did or did not develop RT-associated DRMs. The fact that all of the samples were from plasma suggests that the observed variants were most likely replication competent, which is much less often the case for proviral HIV-1 DNA sequences obtained from peripheral blood mononuclear cells (PBMCs) [33]. The availability of sequences from two time points also provides confirmation that the few observed uncommon variants, such as large deletions, were consistent with virus replication.

268 Contrary to our initial hypothesis, we did not observe co-evolutionary changes between RT and 269 5'-leader sequences. The only 5'-leader position (position 201) that demonstrated a higher likelihood of 270 evolution in samples from individuals who developed RT-associated DRMs is one of the most variable 5'-271 leader positions. However, our study uncovered a previously unreported phenomenon, wherein specific 272 5'-leader positions, particularly positions 200 and 201, exhibited an extraordinarily high likelihood of 273 containing two or more nucleotides each in more than 20% of NGS reads. We corroborated this finding 274 by analyzing two previously published datasets: five published studies of clonal dideoxy-terminator 275 Sanger sequences and six NCBI SRA NGS datasets encompassing the HIV-1 5'-leader.

276 Although HIV-1 is a quasispecies characterized by the presence of multiple circulating variants, 277 the markedly high prevalence of nucleotide mixtures at two particular positions is striking. The 278 prevalence of mixtures in our 80 baseline sequences was 45% for position 200 and 29% for position 201. 279 In our analysis of previously published clonal sequences, these prevalences were 38% and 26%, 280 respectively, and in our analysis of previously published NGS data, these prevalences were 35% and 281 21%, respectively. Moreover, in these analyses, positions 200 and 201 contained mixtures at a 282 frequency several times higher than that observed at any other 5'-leader position or, in the NCBI SRA 283 NGS dataset, at any RT position. The fact that the previously published clonal and NGS datasets

13

contained large numbers of non-subtype B isolates suggests that the propensity of positions 200 and
201 to contain nucleotide mixtures is not limited to one subtype.

286 Positions 200 and 201 are immediately downstream of the PBS, situated opposite to the 287 consecutive A nucleotides at tRNA positions 58 and 57, respectively [9]. The significance of 288 complementarity between the 5'-leader and tRNA at these two positions, however, has not been 289 studied. There are several plausible non-exclusive explanations for the high proportion of mixtures at 290 these two positions. First, these positions may be particularly error prone as they represent the first two 291 nucleotides added following the second strand transfer step during HIV-1 reverse transcription [15]. 292 Second, the presence of multiple circulating variants at these positions may provide an as yet unknown 293 fitness advantage within an individual patient. Third, HIV-1 replication has been shown to be 294 occasionally primed by tRNA5_{Lvs}, as well as tRNA3_{Lvs} [34]; but it is not known whether or how this might 295 influence the development of mutations just following the PBS. Finally, if the tRNA molecules co-296 packaged with genomic RNA re-annealed to the PBS following our nucleic acid extraction procedure but 297 before reverse transcription, this might also influence mutations just following the PBS.

Our study has several limitations. First, our sequences did not encompass the first 36 nucleotides of TAR. The plasma virus samples that we sequenced begin at the start of TAR and could not be amplified without designing primers that bind to this region making it impossible to sequence the nucleotides bound to or upstream of our 5'-prime PCR primer. Several studies have reported that the 5'leader structure is exquisitely sensitive to mutations in TAR [35–37]. Indeed, a single nucleotide difference in the transcription start of TAR has been found to influence the overall structure of the 5'leader [38].

305 Second, our study is also limited because we studied convenience samples. As a result, we were 306 unable to match the three groups of patients for several important characteristics such as year of 307 infection, time between samples, and CD4 count. However, because we found few differences in the

14

evolution of 5'-leader sequence between the three groups of patients and because our main finding, the
extraordinary high proportion of mixtures at positions 200 and 201, was apparent in the baseline
sequences, this limitation is unlikely to have influenced our study's conclusions.

Third, M184V has been shown to increase the fidelity of the HIV-1 RT enzyme [39,40]. Thus, we cannot be certain that the number of mutations in the M184V group was influenced by the development of this mutation. Nonetheless, M184V does not appear to significantly limit the evolutionary potential of viruses containing this mutation *in vitro* and likely *in vivo* [41–43]. Finally, we performed NGS without using unique molecular identifiers (UMIs) [44]. The use of UMIs would have allowed us to precisely quantify each variant within the HIV-1 quasispecies and to thus reliably identify linkages between positions in the same variant [44].

318 In conclusion, this is the first study in which paired circulating plasma HIV-1 5'-leader sequences 319 were obtained from a large number of individuals with well characterized ARV treatment histories at 320 two time points. The study uncovered a previously unreported phenomenon in which several 5'-leader 321 positions, particularly positions 200 and 201, which are immediately downstream of the PBS, often 322 contain high proportions of different nucleotides in the same sample. Data from this study also suggests 323 that nucleotide mixtures at these positions increase with the duration of infection. Future studies 324 employing deep sequencing will provide more insight into this phenomenon by determining whether 325 different nucleotides at positions 200 and 201 are associated with changes at other 5'-leader positions. 326 Additionally, mutational studies will be required to determine the potential biological significance of 327 variations at these positions.

- 328
- 329
- 330
- 331 Acknowledgements

- 332 JN and RWS have been funded in part by an NIH grant R03 Al147632. EVP, JDP and MK have been
- funded in part by an NIH grant U54 Al170856.
- 334
- 335 <u>Conflicts of interest</u>
- 336 The author(s) declare that there are no conflicts of interest.

338	FIGURE LEGENDS
339	Figure 1
340	HIV-1 5'-leader nucleotide differences from HXB2 observed in the 80 baseline sequences superimposed
341	on a diagram of its RNA secondary structure. Nucleotides observed in \ge 20% of reads in more than 10%
342	of sequences are shown in orange; those present in fewer than 10% of sequences are shown in purple.
343	Insertions and deletions are not shown. Positions 1 to 36 were not sequenced. TAR: trans-activation
344	response element (positions 1-57); PolyA: polyadenylation signal (positions 58-104); H1: helix 1 tertiary
345	structure; H2: helix 2 tertiary structure; PBS: primer binding site (positions 182-199); DIS: dimer
346	initiation site (positions 242-278); psi: packaging signal (positions 312-315). The Matrix initiation codon
347	is surrounded by a green box; it is base-paired to the U5 triplet. The primer activation signal nucleotides
348	are colored green, the C-rich region nucleotides are colored yellow, and the PBS nucleotides are colored
349	maroon.
350	
351	Figure 2
352	Distribution of HIV-1 5'-leader nucleotide differences from HXB2 and indels in the 80 baseline sequences
353	and in 1,417 one-per-person Los Alamos National Laboratory HIV Sequence Database (LANL) dataset.
354	
355	Figure 3
356	HIV-1 5'-leader positions ranked according to the frequency with which they contained a mixture of two
357	or more nucleotides. Each nucleotide in a mixture was required to present in \ge 20% of NGS reads.
358	
359	Figure 4

360	Number of HIV-1 5'-leader positions at which a nucleotide or indel exhibited a \geq 4-fold change in its
361	proportion between baseline and follow-up and which was present at a level of \geq 20% at follow-up in
362	each of the three patient groups.
363	
364	Figure 5
365	Neighbor-joining tree containing the 80 baseline and follow-up sequences from this study.
366	Sample IDs for the M184V group are colored blue; those for the NNRTI group are colored
367	yellow; and those for the Control group are colored red. Bootstrap values are indicated at each
368	node of the tree.
369	
370	Figure 6
371	Distribution of positions at which a nucleotide or indel changed its prevalence by \geq 4-fold
372	according to patient group (A) and a table indicating the ten positions that changed most often
373	(B).
374	
375	Supplementary Figure 1
376	HIV-1 5-leader nucleotide differences from the HXB2 sequence observed in 1,417 sequences in
377	the Los Alamos National Laboratories HIV Sequence Database dataset. Superscripts indicate the
378	percentage of times that a nucleotide was reported. Highlighted regions include (1) TAR: trans-
379	activation response element; (2) PolyA: polyadenylation signal loop with a box surrounding the
380	poly A motif; (3) U5; (4) PAS: primer activation signal; (5) PBS: primer binding site; (6) DIS: dimer
381	initiation signal loop with a box surrounding the palindromic DIS; (7) major 5' splicing site; (8)
382	PSI packaging signal; (9) Matrix protein with a box surrounding the start codon.

383

384 <u>Supplementary Figure 2</u>

- 385 Distribution of HIV-1 5'-leader nucleotide differences from HXB2 and indels in the 56 baseline sequences
- 386 from ART-naïve individuals compared with the 24 baseline sequences from ART-experienced individuals.

387		
388		REFERENCES
389	1.	Berkhout, B. Structure and Function of the Human Immunodeficiency Virus Leader RNA. In <i>Progress</i>
390		in Nucleic Acid Research and Molecular Biology; Cohn, W.E., Moldave, K., Eds.; Academic Press,
391		1996: Vol. 54. pp. 1–34.
392	2.	Abbink, T.F.M.; Berkhout, B. A Novel Long Distance Base-Pairing Interaction in Human
393		Immunodeficiency Virus Type 1 RNA Occludes the Gag Start Codon 1 Biol Chem 2003 278
394		11601–11611 doi 10.1074/ibc M210291200
395	З	Song R Kafaje 1 Laughrea M Role of the 57 TAR Stem-Loop and the US-AUG Duplex in
396	0.	Dimerization of HIV-1 Genomic RNA <i>Biochemistry</i> 2008 47 3283–3293 doi:10.1021/bi7023173
397	Л	Isel C : Ehresmann C : Marquet B Initiation of HIV Reverse Transcription Viruses 2010 , 2, 213–
398	т.	243 doi:10.3390/v2010213
399	5.	van Bel, N.; Ghabri, A.; Das, A.T.; Berkhout, B. The HIV-1 Leader RNA is Exquisitely Sensitive to
400	0.	Structural Changes, <i>Virology</i> 2015 , <i>483</i> , 236–252, doi:10.1016/i.virol.2015.03.050.
401	6.	Tomezsko, P.J.; Corbin, V.D.A.; Gupta, P.; Swaminathan, H.; Glasgow, M.; Persad, S.; Edwards, M.D.;
402		Mcintosh, L.: Papenfuss, A.T.: Emery, A.: et al. Determination of RNA Structural Diversity and Its
403		Role in HIV-1 RNA Splicing. <i>Nature</i> 2020 , <i>582</i> , 438–442, doi:10.1038/s41586-020-2253-5.
404	7.	Ye. L.: Gribling-Burrer, AS.: Bohn, P.: Kibe, A.: Börtlein, C.: Ambi, U.B.: Ahmad, S.: Olguin-Nava, M.:
405		Smith. M.: Caliskan. N.: et al. Short- and Long-Range Interactions in the HIV-1 57 UTR Regulate
406		Genome Dimerization and Packaging. Nat Struct Mol Biol 2022 , 29, 306–319, doi:10.1038/s41594-
407		022-00746-2.
408	8.	Keane, S.C.; Summers, M.F. NMR Studies of the Structure and Function of the HIV-1 5'-Leader.
409		Viruses 2016 , <i>8</i> , doi:10.3390/v8120338.
410	9.	Larsen, K.P.; Mathiharan, Y.K.; Kappel, K.; Coey, A.T.; Chen, DH.; Barrero, D.; Madigan, L.; Puglisi,
411		J.D.; Skiniotis, G.; Puglisi, E.V. Architecture of an HIV-1 Reverse Transcriptase Initiation Complex.
412		Nature 2018 , 557, 118–122, doi:10.1038/s41586-018-0055-9.
413	10.	Ha, B.; Larsen, K.P.; Zhang, J.; Fu, Z.; Montabana, E.; Jackson, L.N.; Chen, DH.; Puglisi, E.V. High-
414		Resolution View of HIV-1 Reverse Transcriptase Initiation Complexes and Inhibition by NNRTI
415		Drugs. Nat Commun 2021 , 12, 2500, doi:10.1038/s41467-021-22628-9.
416	11.	Dutilleul, A.; Rodari, A.; Van Lint, C. Depicting HIV-1 Transcriptional Mechanisms: A Summary of
417		What We Know. <i>Viruses</i> 2020 , <i>12</i> , 1385, doi:10.3390/v12121385.
418	12.	Emery, A.; Swanstrom, R. HIV-1: To Splice or Not to Splice, That Is the Question. Viruses 2021, 13,
419		181, doi:10.3390/v13020181.
420	13.	Lu, K.; Heng, X.; Summers, M.F. Structural Determinants and Mechanism of HIV-1 Genome
421		Packaging. <i>Journal of Molecular Biology</i> 2011 , <i>410</i> , 609–633, doi:10.1016/j.jmb.2011.04.029.
422	14.	Mailler, E.; Bernacchi, S.; Marquet, R.; Paillart, JC.; Vivet-Boudou, V.; Smyth, R.P. The Life-Cycle of
423		the HIV-1 Gag–RNA Complex. <i>Viruses 2016, 8,</i> 248, doi:10.3390/v8090248.
424	15.	Krupkin, M.; Jackson, L.N.; Ha, B.; Puglisi, E.V. Advances in Understanding the Initiation of HIV-1
425		Reverse Transcription. Current Opinion in Structural Biology 2020, 65, 175–183,
426		doi:10.1016/j.sbi.2020.07.005.
427	16.	Chen, S.; Zhou, Y.; Chen, Y.; Gu, J. Fastp: An Ultra-Fast All-in-One FASTQ Preprocessor.
428		<i>Bioinformatics</i> 2018 , <i>34</i> , i884–i890, doi:10.1093/bioinformatics/bty560.
429	17.	Li, H. Minimap2: Pairwise Alignment for Nucleotide Sequences. <i>Bioinformatics</i> 2018 , <i>34</i> , 3094–3100,
430		doi:10.1093/bioinformatics/bty191.
431	18.	Li, H.; Handsaker, B.; Wysoker, A.; Fennell, T.; Ruan, J.; Homer, N.; Marth, G.; Abecasis, G.; Durbin, R.
432		The Sequence Alignment/Map Format and SAMtools. <i>Bioinformatics</i> 2009 , <i>25</i> , 2078–2079,
433		doi:10.1093/bioinformatics/btp352.

121	10	Pice By Longdon Ly Bloashy A. EMBOSS: The European Melecular Biology Open Seftware Suite
434	19.	Trands in Canatics 2000, 16, 276, 277, doi:10.1016/S0168.9525/00/02024.2
435	20	Katob K : Erith M C. Adding Unaligned Sequences into an Existing Alignment Using MAEET and
430	20.	LAST <i>Bioinformatics</i> 2012 , 22, 2144, 2146, doi:10.1002/bioinformatics/btsE79
437	21	Novitsky, V.A.; Montano, M.A.; Melano, M.F.; Ponijfo, P.; Vannberg, F.; Foloy, P.T.; Ndung'u, T.D.;
420	ΖΙ.	Novitsky, V.A.; Montano, M.A.; McLane, M.F.; Kenjito, B.; Valinberg, F.; Foley, B.F.; Nuulig u, T.P.;
439		Ranman, W.; Waknema, W.J.; Warlink, R.; et al. Wolecular Cioning and Phylogenetic Analysis of
440		Human Immunodeficiency virus Type I Subtype C: A Set of 23 Full-Length Ciones from Botswana. J
441 442	22	VIIUI 1999, 73, 4427-4432. Polland M. Toyanabutra S. doCamp A.C. Erahm N. Cilbort D.P. Sandars Buell E. Heath L.
44Z 112	ZZ.	Magazet, C.A., Poso, M., Pradfield, A., et al. Constitution for Vascination on Proakthrough HIV 1
445		Sequences from the STED Trial Not Med 2011 , 17, 266, 271, doi:10.1029/nm.2216
444	22	Ochsenhauer C. Edmonds T.C. Ding H. Koolo P.F. Docker L. Solazar M.C. Solazar Conzolaz
445	23.	Unsemblauer, C.; Edmonds, T.G.; Ding, H.; Reele, B.F.; Decker, J.; Salazar, M.G.; Salazar-Gonzalez,
440		J.F.; Shallock, K.; Haynes, B.F.; Shaw, G.W.; et al. Generation of Thanshilled/Founder Hiv-1
447 770		Infectious Molecular Clones and Characterization of Their Replication Capacity in CD4 1
440		doi:10.1128/IVU.061E7.11
449	24	UUI:1U.1126/JVI.00157-11. Devrich N.F. Coo, F. Li, H. Ciergi, F.F. Perhien, H.L. Perrich, F.H. Zaiie, L. Juar, S.S. Decker, J.M.
450	24.	Kumar A: et al. Phonotypic Proportion of Transmitted Founder HIV 1. Proc. Natl. Acad. Sci. 11.5.4
451		2012 110 6626 6622 doi:10.1072/page 120/282110
452	25	Condim M V D · Sherrill Mix S · Biballat Rucha E · Russell R M · Trimbali S · Smith A G · Li V · Liu
455	25.	W · Avitto A N · DeVoto I C · et al. Heightened Resistance to Host Type 1 Interferons
454		Characterizes HIV 1 at Transmission and after Antiretroviral Therapy Interruption. Sci Transl Med
455		2021 13 eabd8179 doi:10.1126/scitranslmed.abd8179
457	26	Gall A · Ferns B · Morris C · Watson S · Cotten M · Robinson M · Berry N · Pillay D · Kellam P
457 158	20.	Universal Amplification Next-Generation Sequencing and Assembly of HIV-1 Genomes 1 Clin
450		Microbiol 2012 50 3838–3844 doi:10.1128/ICM.01516-12
460	27	Illingworth C L B : Roy S : Reale M A : Tutill H : Williams B : Breuer L On the Effective Denth of
461	27.	Viral Sequence Data Virus Evol 2017 3 vex030 doi:10.1093/ve/vex030
462	28	Fedonin G.G.: Fantin Y.S.: Favorov A.V.: Shipulin G.A.: Neverov A.D. VirGenA: A.Reference-Based
463	20.	Assembler for Variable Viral Genomes. <i>Briefings in Bioinformatics</i> 2019 , <i>20</i> , 15–25.
464		doi:10.1093/bib/bbx079.
465	29.	Vilsker, M.: Moosa, Y.: Nooii, S.: Fonseca, V.: Ghysens, Y.: Dumon, K.: Pauwels, R.: Alcantara, L.C.:
466		Vanden Evnden, E.: Vandamme, AM.: et al. Genome Detective: An Automated System for Virus
467		Identification from High-Throughput Sequencing Data. <i>Bioinformatics</i> 2019 . <i>35</i> . 871–873.
468		doi:10.1093/bioinformatics/bty695.
469	30.	Zhang, Y.: Wymant, C.: Laevendecker, O.: Grabowski, M.K.: Hall, M.: Hudelson, S.: Piwowar-
470		Manning, E.: McCauley, M.: Gamble, T.: Hosseinipour, M.C.: et al. Evaluation of Phylogenetic
471		Methods for Inferring the Direction of Human Immunodeficiency Virus (HIV) Transmission: HIV
472		Prevention Trials Network (HPTN) 052. Clin Infect Dis 2020, 72, 30–37, doi:10.1093/cid/ciz1247.
473	31.	Kouyos, R.D.; von Wyl, V.; Yerly, S.; Böni, J.; Rieder, P.; Joos, B.; Taffé, P.; Shah, C.; Bürgisser, P.;
474		Klimkait, T.; et al. Ambiguous Nucleotide Calls From Population-Based Sequencing of HIV-1 Are a
475		Marker for Viral Diversity and the Age of Infection. <i>Clinical Infectious Diseases</i> 2011 , <i>52</i> , 532–539.
476		doi:10.1093/cid/ciq164.
477	32.	Andersson, E.; Shao, W.; Bontell, I.; Cham, F.; Cuong, D.D.; Wondwossen, A.; Morris, L.; Hunt, G.;
478		Sönnerborg, A.; Bertagnolio, S.; et al. Evaluation of Sequence Ambiguities of the HIV-1 Pol Gene as
479		a Method to Identify Recent HIV-1 Infection in Transmitted Drug Resistance Surveys. Infection,
480		Genetics and Evolution 2013 , 18, 125–131, doi:10.1016/j.meegid.2013.03.050.

- 33. Bruner, K.M.; Murray, A.J.; Pollack, R.A.; Soliman, M.G.; Laskey, S.B.; Capoferri, A.A.; Lai, J.; Strain,
 M.C.; Lada, S.M.; Hoh, R.; et al. Defective Proviruses Rapidly Accumulate during Acute HIV-1
 Infection. *Nat Med* 2016, *22*, 1043–1049, doi:10.1038/nm.4156.
- 484 34. Das, A.T.; Vink, M.; Berkhout, B. Alternative TRNA Priming of Human Immunodeficiency Virus Type 1
 485 Reverse Transcription Explains Sequence Variation in the Primer-Binding Site That Has Been
 486 Attributed to APOBEC3G Activity. *Journal of Virology* 2005, *79*, 3179–3181,
- 487 doi:10.1128/jvi.79.5.3179-3181.2005.
- 488 35. Huthoff, H.; Berkhout, B. Mutations in the TAR Hairpin Affect the Equilibrium between Alternative
 489 Conformations of the HIV-1 Leader RNA. *Nucleic Acids Research* 2001, *29*, 2594–2600,
 490 doi:10.1093/nar/29.12.2594.
- 491 36. Vrolijk, M.M.; Ooms, M.; Harwig, A.; Das, A.T.; Berkhout, B. Destabilization of the TAR Hairpin
 492 Affects the Structure and Function of the HIV-1 Leader RNA. *Nucleic Acids Research* 2008, *36*,
 493 4352–4363, doi:10.1093/nar/gkn364.
- 494 37. Ding, P.; Kharytonchyk, S.; Kuo, N.; Cannistraci, E.; Flores, H.; Chaudhary, R.; Sarkar, M.; Dong, X.;
 495 Telesnitsky, A.; Summers, M.F. 5'-Cap Sequestration Is an Essential Determinant of HIV-1 Genome
 496 Packaging. *Proc Natl Acad Sci U S A* 2021, *118*, e2112475118, doi:10.1073/pnas.2112475118.
- 497 38. Brown, J.D.; Kharytonchyk, S.; Chaudry, I.; Iyer, A.S.; Carter, H.; Becker, G.; Desai, Y.; Glang, L.; Choi,
 498 S.H.; Singh, K.; et al. Structural Basis for Transcriptional Start Site Control of HIV-1 RNA Fate.
 499 Science 2020, 368, 413–417, doi:10.1126/science.aaz7959.
- S00 39. Oude Essink, B.B.; Back, N.K.T.; Berkhout, B. Increased Polymerase Fidelity of the 3TC-Resistant
 S01 Variants of HIV-1 Reverse Transcriptase. *Nucleic Acids Research* 1997, 25, 3212–3217,
 S02 doi:10.1093/nar/25.16.3212.
- 40. Hsu, M.; Inouye, P.; Rezende, L.; Richard, N.; Li, Z.; Prasad, V.R.; Wainberg, M.A. Higher Fidelity of
 RNA-Dependent DNA Mispair Extension by M184V Drug-Resistant than Wild-Type Reverse
 Transcriptase of Human Immunodeficiency Virus Type 1. *Nucleic Acids Research* 1997, 25, 4532–
 4536, doi:10.1093/nar/25.22.4532.
- 507 41. Jonckheere, H.; Witvrouw, M.; De Clercq, E.; Anné, J. Short Communication: Lamivudine Resistance
 508 of HIV Type 1 Does Not Delay Development of Resistance to Nonnucleoside HIV Type 1-Specific
 509 Reverse Transcriptase Inhibitors as Compared with Wild-Type HIV Type 1. *AIDS Research and*510 *Human Retroviruses* 1998, 14, 249–253, doi:10.1089/aid.1998.14.249.
- 511 42. Keulen, W.; van Wijk, A.; Schuurman, R.; Berkhout, B.; Boucher, C.A.B. Increased Polymerase Fidelity
 512 of Lamivudine-Resistant HIV-1 Variants Does Not Limit Their Evolutionary Potential. *AIDS* 1999, *13*,
 513 1343.
- 514 43. Stockdale, A.J.; Saunders, M.J.; Boyd, M.A.; Bonnett, L.J.; Johnston, V.; Wandeler, G.; Schoffelen,
 515 A.F.; Ciaffi, L.; Stafford, K.; Collier, A.C.; et al. Effectiveness of Protease Inhibitor/Nucleos(t)lde
 516 Reverse Transcriptase Inhibitor–Based Second-Line Antiretroviral Therapy for the Treatment of
 517 Human Immunodeficiency Virus Type 1 Infection in Sub-Saharan Africa: A Systematic Review and
 518 Meta-Analysis. *Clinical Infectious Diseases* 2018, *66*, 1846–1857, doi:10.1093/cid/cix1108.
- 519 44. Zhou, S.; Hill, C.S.; Spielvogel, E.; Clark, M.U.; Hudgens, M.G.; Swanstrom, R. Unique Molecular
 520 Identifiers and Multiplexing Amplicons Maximize the Utility of Deep Sequencing To Critically Assess
 521 Population Diversity in RNA Viruses. ACS Infect. Dis. 2022, 8, 2505–2514,
- 522 doi:10.1021/acsinfecdis.2c00319.
- 523

524 Table 1. Description of the 80 Individuals Undergoing Baseline and Follow-Up HIV-1 5'-Leader Sequencing

525

				NNRTI-Resistance		P value ¹		
		Control Group (n=33)	M184V Group (n=29)	Group (n=19)	Control vs. M184V	Control vs. NNRTI	M184V vs. NNRTI	
Sex		30 male / 2 female	24 male / 5 female	16 male / 3 female	NS	NS	NS	
Age (IQR)		39 (26.8-51)	42 (33-47)	41 (33-48)	NS	NS	NS	
Year (IQR)		2011 (2006-2014)	2001 (2001-2004)	2004 (2001-2010)	<0.001	0.003	NS	
Baseline ART	history ²	Naïve: 32	NRTI-naïve: 19 NRTI-experienced: 10	NNRTI-naïve: 16 NNRTI-experienced: 3	-	-	-	
CD4 (IQR)	Baseline	402.5 (296-503.5)	83 (35-252)	160 (78-259)	<0.001	<0.001	NS	
	Follow-up	315 (221-472.8)	185 (81-312)	192 (98-255)	0.007	0.01	NS	
VL (IQR)	Baseline	4.6 (4.1-4.9)	5.2 (4.6-5.6)	4.6 (4.4-5.6)	0.002	NS	NS	
	Follow-up	4.8 (4.3-5)	4.4 (4.1-4.8)	4.8 (4.5-5)	NS	NS	NS	
Months (IQR)	3	12.5 (2-21.5)	20 (7-36)	39 (16.5-54.5)	0.04	0.01	0.04	
<i>Pol</i> genetic distance (IQR) ⁴		0.75% (0.44%-1.23%)	2.17% (1.6%-2.84%)	1.92% (1.47%-2.98%)	<0.001	<0.001	NS	

526

527 <u>Footnotes</u>: ¹Wilcoxon Rank Sum Tests were used to compare all median values. Fisher's exact tests were used to compare proportions (e.g., 528 proportion that were male). ²In the M184V Group, 9 of the 10 individuals who were NRTI-experienced individuals at baseline had received a 3TC-529 or FTC-containing regimen but none had developed M184V (or M184I) prior to initial sampling. In the NNRTI-resistance group, 6 of the 16 530 individuals who were NNRTI-naïve at baseline were completely ART-naïve; none of the 3 NNRTI-experienced individuals had previous NNRTI-531 resistance mutations. ³Months between the baseline and follow-up samples. ⁴The percentage of nucleotides that differed between baseline and 532 follow-up in the HIV-1 *pol* sequence performed for clinical purposes at the time the samples were initially obtained. The *pol* sequence usually 533 encompassed the complete protease and the first 300 RT codons.

Table 2. Proportion of HIV-1 5'-Leader Positions Containing a Mixture of Nucleotides in Sampled Viruses in this Study, in Previously Published
 Studies in GenBank, and in NGS Studies in the NCBI Sequence Read Archive (SRA)

- 6	\mathbf{r}	7
ר	- 5	1
_	-	

Position	Baseline Samples from this Study (n=80 individuals) ¹	Published Studies of Individuals with Multiple Clones (GenBank) (n=42 individuals) ²	Published Studies of Individuals Undergoing NGS (NCBI SRA) (n=295 individuals) ³
200	45.0%	38.1%	34.9%
201	28.8%	26.2%	21.1%
304	15.0%	4.8%	4.1%
224	10.0%	9.5%	6.1%
354	10.0%	2.4%	1.4%
305	8.8%	16.7%	6.0%
152	7.5%	11.9%	6.8%
286	6.3%	9.5%	5.8%
96	6.3%	6.9%	8.2%
263	6.3%	2.4%	2.7%
281	5.0%	11.9%	1.5%
47	5.0%	4.8%	8.2%
215	5.0%	7.1%	2.5%
227	5.0%	4.8%	2.7%
353	5.0%	2.4%	1.0%

538

539 Footnote: ¹A position was considered to have a mixture if at least one non-consensus nucleotide was present in \geq 20% of reads. ²Data were

540 obtained from five publications reporting \geq 3 clones per individual from \geq 5 individuals. A total of 294 sequences were performed (i.e., a mean of

541 7 clones per individual). A position was considered to have a mixture if at least one clone had a non-consensus nucleotide. Thirty-one individuals

542 (74%) had subtype B viruses and 11 patients had subtype C viruses. ³A position was considered to have a mixture if at least one non-consensus

543 nucleotide was present in ≥20% of reads. Sixty-four percent of sequences belonged to subtype C; 21% to subtype B; and 15% to other subtypes

544 or circulating recombinant forms.











- 0.005

A



Top 10 positions

B

Position	Control	M184V	NNRTI
FUSILION	(n=32)	(n=29)	(n=19)
200	9% (3)	31% (9)	26% (5)
201	0% (0)	31% (9)	21% (4)
152	3% (1)	14% (4)	5% (1)
305	9% (3)	10% (3)	5% (1)
96	6% (2)	10% (3)	5% (1)
227	3% (1)	10% (3)	5% (1)
354	3% (1)	10% (3)	5% (1)
265	16% (5)	7% (2)	16% (3)
263	12% (4)	7% (2)	16% (3)
47	6% (2)	7% (2)	16% (3)